These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

399 related articles for article (PubMed ID: 30572736)

  • 41. Significance of tumor microenvironment in acquiring resistance to vascular endothelial growth factor-tyrosine kinase inhibitor and recent advance of systemic treatment of clear cell renal cell carcinoma.
    Mikami S; Mizuno R; Kosaka T; Tanaka N; Kuroda N; Nagashima Y; Okada Y; Oya M
    Pathol Int; 2020 Oct; 70(10):712-723. PubMed ID: 32652869
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Tivozanib: practical implications for renal cell carcinoma and other solid tumors.
    Berge EM; Bowles DW; Flaig TW; Lam ET; Jimeno A
    Drugs Today (Barc); 2013 May; 49(5):303-15. PubMed ID: 23724410
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Sorafenib: scientific rationales for single-agent and combination therapy in clear-cell renal cell carcinoma.
    Gollob JA
    Clin Genitourin Cancer; 2005 Dec; 4(3):167-74. PubMed ID: 16425993
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Safety of available treatment options for renal cell carcinoma.
    Derosa L; Albiges L; Massard C; Loriot Y; Fizazi K; Escudier B
    Expert Opin Drug Saf; 2016 Aug; 15(8):1097-106. PubMed ID: 27142582
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of Second-line Targeted Therapy for Renal Cell Carcinoma According to Change from Baseline in International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Category.
    Davis ID; Xie W; Pezaro C; Donskov F; Wells JC; Agarwal N; Srinivas S; Yuasa T; Beuselinck B; Wood LA; Ernst DS; Kanesvaran R; Knox JJ; Pantuck A; Saleem S; Alva A; Rini BI; Lee JL; Choueiri TK; Heng DYC
    Eur Urol; 2017 Jun; 71(6):970-978. PubMed ID: 27771126
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway.
    Roodhart JM; Langenberg MH; Witteveen E; Voest EE
    Curr Clin Pharmacol; 2008 May; 3(2):132-43. PubMed ID: 18690886
    [TBL] [Abstract][Full Text] [Related]  

  • 47. A systematic review of sequencing and combinations of systemic therapy in metastatic renal cancer.
    Albiges L; Choueiri T; Escudier B; Galsky M; George D; Hofmann F; Lam T; Motzer R; Mulders P; Porta C; Powles T; Sternberg C; Bex A
    Eur Urol; 2015 Jan; 67(1):100-110. PubMed ID: 24841777
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Advanced renal cell carcinoma: current and emerging management strategies.
    Escudier B
    Drugs; 2007; 67(9):1257-64. PubMed ID: 17547470
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Lenvatinib for the treatment of renal cell carcinoma.
    Roviello G; Corona SP; Bozza G; Aieta M; Generali D; Rodriquenz MG; Mileo AM; Imperatori M; Ianza A; Conca R; Sobhani N
    Expert Opin Investig Drugs; 2018 May; 27(5):507-512. PubMed ID: 29718721
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Novel agents, combinations and sequences for the treatment of advanced renal cell carcinoma: When is the revolution coming?
    Santoni M; Rizzo M; Burattini L; Berardi R; Carteni G; Cascinu S
    Curr Cancer Drug Targets; 2013 Mar; 13(3):313-25. PubMed ID: 23190497
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Building on a foundation of VEGF and mTOR targeted agents in renal cell carcinoma.
    Flaherty KT; Puzanov I
    Biochem Pharmacol; 2010 Sep; 80(5):638-46. PubMed ID: 20382128
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Bisphosphonates and vascular endothelial growth factor-targeted drugs in the treatment of patients with renal cell carcinoma metastatic to bone.
    Vrdoljak E; Rini B; Schmidinger M; Omrčen T; Torday L; Szczylik C; Sella A
    Anticancer Drugs; 2013 Jun; 24(5):431-40. PubMed ID: 23511427
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma.
    Motzer RJ; Michaelson MD; Redman BG; Hudes GR; Wilding G; Figlin RA; Ginsberg MS; Kim ST; Baum CM; DePrimo SE; Li JZ; Bello CL; Theuer CP; George DJ; Rini BI
    J Clin Oncol; 2006 Jan; 24(1):16-24. PubMed ID: 16330672
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Dll4 blockade potentiates the anti-tumor effects of VEGF inhibition in renal cell carcinoma patient-derived xenografts.
    Miles KM; Seshadri M; Ciamporcero E; Adelaiye R; Gillard B; Sotomayor P; Attwood K; Shen L; Conroy D; Kuhnert F; Lalani AS; Thurston G; Pili R
    PLoS One; 2014; 9(11):e112371. PubMed ID: 25393540
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Protein kinase inhibitors in renal cell carcinoma.
    Daste A; Grellety T; Gross-Goupil M; Ravaud A
    Expert Opin Pharmacother; 2014 Feb; 15(3):337-51. PubMed ID: 24328606
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Axitinib in metastatic renal cell carcinoma.
    Albiges L; Gizzi M; Carton E; Escudier B
    Expert Rev Anticancer Ther; 2015 May; 15(5):499-507. PubMed ID: 25907705
    [TBL] [Abstract][Full Text] [Related]  

  • 57. New agents and new targets for renal cell carcinoma.
    Philips GK; Atkins MB
    Am Soc Clin Oncol Educ Book; 2014; ():e222-7. PubMed ID: 24857106
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Vascular endothelial growth factor-targeted therapy in renal cell carcinoma: current status and future directions.
    Rini BI
    Clin Cancer Res; 2007 Feb; 13(4):1098-106. PubMed ID: 17317817
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Investigational multitargeted kinase inhibitors in development for head and neck neoplasms.
    Sola AM; Johnson DE; Grandis JR
    Expert Opin Investig Drugs; 2019 Apr; 28(4):351-363. PubMed ID: 30753792
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Promoter methylation status of VEGF receptor genes: a possible epigenetic biomarker to anticipate the efficacy of intracellular-acting VEGF-targeted drugs in cancer cells.
    Kim J; Hwang J; Jeong H; Song HJ; Shin J; Hur G; Park YW; Lee SH; Kim J
    Epigenetics; 2012 Feb; 7(2):191-200. PubMed ID: 22395469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.